Key points are not available for this paper at this time.
The publication of randomized controlled trials (RCTs) enables dissemination of the findings of clinical investigations that aim to improve clinical practice. These documents serve as sources of information that medical providers seek to apply evidence-based medicine to patient care (1). RCTs are precisely regimented, and their protocols provide clear instructions regarding drug administration, patient monitoring, toxicity management, and therapeutic dose modifications. These instructions should be capable of reproduction once the trial results are published to enable clinicians to replicate study design and methodology and achieve similar outcomes. Ideally, the trial details that are disclosed should be readily accessible, easy to interpret, and immediately transferable to the clinical setting (2). The International Committee of Medical Journal Editors has established reporting guidelines that are applicable to the preparation of all RCT manuscripts, and most major oncology journals reference these guidelines in their author submission standards. Despite these standards, there is no set policy or accepted format for reporting details associated with drug administration or patient monitoring (2). Thus, published reports of investigations of chemotherapies and/or biologic therapies often lack some details needed for safe and effective translation to clinical application.
Duff et al. (Thu,) studied this question.